Migdal Insurance & Financial Holdings’s Bio-Rad Laboratories Class A BIO Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,539	Closed	-$1.31M	–	657
2020 Q3	$1.31M	Sell	2,539 -2,201	-46%	-$1.11M	0.02%	249
2020 Q2	$2.14M	Buy	4,740 +1,547	+48%	+$683K	0.03%	174
2020 Q1	$1.12M	Sell	3,193 -852	-21%	-$313K	0.03%	163
2019 Q4	$1.5M	Buy	4,045 +561	+16%	+$198K	0.03%	171
2019 Q3	$1.16M	Buy	3,484 +1,042	+43%	+$340K	0.02%	230
2019 Q2	$763K	Buy	2,442 +708	+41%	+$212K	0.02%	271
2019 Q1	$530K	Buy	1,734 +1,035	+148%	+$279K	0.01%	290
2018 Q4	$162K	Buy	+699	New	+$188K	﹤0.01%	403

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Migdal Insurance & Financial Holdings's BIO Position: Q4 2020 in Review

Migdal Insurance & Financial Holdings sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2020, closing a stake of 2,539 shares — an estimated $1.31M sold.

Migdal Insurance & Financial Holdings first reported a position in BIO in Q4 2018 and held it in 8 quarters. The position peaked at $2.14M in Q2 2020. 491 funds tracked by Wall St. Rank hold BIO as of Q4 2020.

Migdal Insurance & Financial Holdings reported no remaining Bio-Rad Laboratories Class A position as of Q4 2020 after selling out during the quarter.
Migdal Insurance & Financial Holdings sold 2,539 Bio-Rad Laboratories Class A shares in Q4 2020, an estimated $1.31M.
Migdal Insurance & Financial Holdings first reported a position in Bio-Rad Laboratories Class A in Q4 2018 and held it in 8 quarters.
Migdal Insurance & Financial Holdings's Bio-Rad Laboratories Class A position peaked at $2.14M in Q2 2020.
491 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2020.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q4 2020, filed 8 Feb 2021.